×
![]( "Buchcover ISBN 9781118097779")
„Contributors mostly from pharmaceutical companies provide a systematic introduction to characterizing metabolites, which has become an important element in drug discovery. They write for scientists involved in designing, developing, and advancing metabolic characterizations for drug discovery and development, and for researchers and students in fields that might call for such characterizations.“ (Book News Inc., February 2011)
Biotransformation and Metabolite Elucidation of Xenobiotics
Characterization and Identification
herausgegeben von Ala F. NassarThe goal of this book is to improve the readers' knowledge ofmetabolite elucidation in drug metabolism by exposing them to indepth coverage of the biotransformation of xenobiotics, strategiesfor identifying and characterizing metabolites, FDA guidelines, andcase studies on how to improve the decision-making process instructural modification of drug candidates to reduce toxicity.
The book consists of 8 chapters; it first provides anintroduction on biotransformation of xenobiotics, and then presentsmodern approaches and strategies for dealing with metabolitecharacterization, using tools such as LC-MS, H-D exchange, stableisotopes LC-MS-NMR, and radiolabeled compounds. Also, strategiesfor dealing with reactive intermediates in drug discovery anddevelopment are presented as well as case studies on improving thedecision-making process in the structural modification of drugcandidates. The last chapter discusses the regulatory perspectivesof safety testing of drug metabolites and why, how, and when totest their safety.
The book consists of 8 chapters; it first provides anintroduction on biotransformation of xenobiotics, and then presentsmodern approaches and strategies for dealing with metabolitecharacterization, using tools such as LC-MS, H-D exchange, stableisotopes LC-MS-NMR, and radiolabeled compounds. Also, strategiesfor dealing with reactive intermediates in drug discovery anddevelopment are presented as well as case studies on improving thedecision-making process in the structural modification of drugcandidates. The last chapter discusses the regulatory perspectivesof safety testing of drug metabolites and why, how, and when totest their safety.
